Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr 28;5(6):762-765.
doi: 10.1016/j.ekir.2020.04.014. eCollection 2020 Jun.

No Change in Nocturia After NOCTURNE

Esther Meijer  1 , Judith E Heida  1 , Ron T Gansevoort  1
Affiliations
Editorial

No Change in Nocturia After NOCTURNE

Esther Meijer et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The V2 receptor antagonist tolvaptan induces a decrease in urine osmolarity that is dose dependent until the highest dose used in trials and in clinical practice. ∗P < 0.05; ∗∗ P < 0.01; ∗∗∗P < 0.001.
See this image and copyright information in PMC

Comment on

References

    1. Perrone R.D., Chapman A.B., Oberdhan D. A randomized trial of modified-release versus immediate-release tolvaptan in ADPKD. Kidney Int Rep. 2020;5:790–800. - PMC - PubMed
    1. Perrone R.D., Chapman A.B., Oberdhan D. The NOCTURNE randomized trial comparing 2 tolvaptan formulations. Kidney Int Rep. 2020;5:801–812. - PMC - PubMed
    1. Gattone V.H., Wang X., Harris P.C., Torres V.E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323–1326. - PubMed
    1. Torres V.E., Chapman A.B., Devuyst O. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–2418. - PMC - PubMed
    1. Torres V.E., Chapman A.B., Devuyst O. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930–1942. - PubMed

LinkOut - more resources